The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Open accessAbstract
High-grade serous ovarian cancer (HGSC) exhibits extensive malignant clonal diversity with widespread but non-random patterns of disease dissemination. We investigated whether local immune microenvironment factors shape tumor progression properties at the interface of tumor-infiltrating lymphocytes (TILs) and cancer cells. Through multi-region study of 212 samples from 38 patients with whole-genome sequencing, immunohistochemistry, histologic image analysis, gene expression profiling, and T and B cell receptor sequencing, we identified three immunologic subtypes across samples and extensive within-patient diversity. Epithelial CD8+ TILs negatively associated with malignant diversity, reflecting immunological pruning of tumor clones inferred by neoantigen depletion, HLA I loss of heterozygosity, and spatial tracking between T cell and tumor clones. In addition, combinatorial prognostic effects of mutational processes and immune properties were observed, illuminating how specific genomic aberration types associate with immune response and impact survival. We conclude that within-patient spatial immune microenvironment variation shapes intraperitoneal malignant spread, provoking new evolutionary perspectives on HGSC clonal dispersion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
The Analysis of Spatial Association by Use of Distance Statistics
Getis, A., & Ord, J. K. (1992) · Geographical Analysis · doi:10.1111/j.1538-4632.1992.tb00261.x · Cited by 6,276
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
MiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,722
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · cited 2×
“To provide context, we also considered other known mechanisms of immune escape, including anatomic site, disruption of antigen presentation machinery (Yoshihama et al., 2016), and expression of immunosuppressive factors (Spranger et al., 2013; Rooney et al., 2015).”
Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,635
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
PyClone: statistical inference of clonal population structure in cancer
Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 999
Self-citationOptiType: precision HLA typing from next-generation sequencing data
Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., & Kohlbacher, O. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu548 · Cited by 769
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Kroeger, D. R., Milne, K., & Nelson, B. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2762 · Cited by 610
Self-citationNielsen, J. S., Sahota, R. A., Milne, K., Kost, S. E., Nesslinger, N. J., Watson, P. H., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0234 · Cited by 553
Self-citationJiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458
Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
Yuan, Y., Failmezger, H., Rueda, O. M., Ali, H. R., Gräf, S., Chin, S.-F., Schwarz, R. F., Curtis, C., Dunning, M. J., Bardwell, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004330 · Cited by 426
Self-citationEffector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L. M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4230 · Cited by 421
Self-citationSpatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P. J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 400
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry-Maharaj, A., Toloczko, A., Hein, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3290 · Cited by 394
Self-citationHa, G., Roth, A., Khattra, J., Ho, J., Yap, D., Prentice, L. M., Melnyk, N., McPherson, A., Bashashati, A., Laks, E., et al. (2014) · Genome Research · doi:10.1101/gr.180281.114 · Cited by 371
Self-citationDivergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer
McPherson, A., Roth, A., Laks, E., Masud, T., Bashashati, A., Zhang, A. W., Ha, G., Biele, J., Yap, D., Wan, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3573 · Cited by 340
Self-citationNLRC5/MHC class I transactivator is a target for immune evasion in cancer
Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602069113 · Cited by 276
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L. M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 273
Self-citationCancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A., & Gerlinger, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.11.003 · Cited by 248
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 199
Lo, C. S., Sanii, S., Kroeger, D. R., Milne, K., Talhouk, A., Chiu, D. S., Rahimi, K., Shaw, P. A., Clarke, B. A., & Nelson, B. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1433 · Cited by 172
Self-citationWick, D. A., Webb, J. R., Nielsen, J. S., Martin, S. D., Kroeger, D. R., Milne, K., Castellarin, M. L., Twumasi‐Boateng, K., Watson, P. H., Holt, R. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2147 · Cited by 167
Self-citationnCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
Cesano, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0088-7 · Cited by 156
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 153
Nawaz, S., Heindl, A., Koelble, K., & Yuan, Y. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.37 · Cited by 147
Self-citationFeature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data
Ding, J., Bashashati, A., Roth, A. J. L., Oloumi, A., Tse, K., Zeng, T., Haffari, G., Hirst, M., Marra, M. A., Condon, A., et al. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr629 · Cited by 146
Self-citationPopova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N. K., Mueller, C. R., Raynal, V., Mariani, O., Sastre-Garau, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2128 · Cited by 130
Smid, M., Rodríguez-González, F. G., Sieuwerts, A. M., Salgado, R., der Smissen, W. J. C. P., van der Vlugt‐Daane, M., van Galen, A., Nik‐Zainal, S., Staaf, J., Brinkman, A. B., et al. (2016) · Nature Communications · doi:10.1038/ncomms12910 · Cited by 106
Efficient molecular subtype classification of high‐grade serous ovarian cancer
Leong, H. S., Galletta, L., Etemadmoghadam, D., George, J., Study, T. A. O. C., Köbel, M., Ramus, S. J., & Bowtell, D. D. L. (2015) · The Journal of Pathology · doi:10.1002/path.4536 · Cited by 95
Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data
Emerson, R., Sherwood, A., Desmarais, C., Malhotra, S., Phippard, D., & Robins, H. S. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.02.002 · Cited by 72
Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells
Ternette, N., Yang, H., Partridge, T., Llano, A., Cedeño, S., Fischer, R., Charles, P. D., Dudek, N. L., Mothe, B., Casal, M. C., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201545890 · Cited by 58
Li, H. M., Hiroi, T., Zhang, Y., Shi, A., Chen, G., De, S., Metter, E. J., Wood, W. H., Sharov, A. A., Milner, J. D., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.6a0215-071rr · Cited by 55
Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
Auer, K., Bachmayr-Heyda, A., Sukhbaatar, N., Aust, S., Schmetterer, K. G., Meier, S. M., Gerner, C., Grimm, C., Horvat, R., & Pils, D. (2016) · Oncotarget · doi:10.18632/oncotarget.11038 · Cited by 47
Nelson, B. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.004 · Cited by 39
Self-citationReMixT: clone-specific genomic structure estimation in cancer
McPherson, A., Roth, A. J. L., Ha, G., Chauve, C., Steif, A., de Souza, C. P. E., Eirew, P. D., Bouchard‐Côté, A., Aparicio, S. A. J. R., Şahinalp, S. C., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1267-2 · Cited by 36
Self-citationHeindl, A., Lan, C., Rodrigues, D. N., Koelble, K., & Yuan, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12106 · Cited by 33
Self-citationSomatic Variation of T-Cell Receptor Genes Strongly Associate with HLA Class Restriction
Klarenbeek, P. L., Doorenspleet, M. E., Esveldt, R. E., van Schaik, B. D. C., Lardy, N. M., van Kampen, A. H. C., Tak, P. P., Plenge, R. M., Baas, F., de Bakker, P. I. W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140815 · Cited by 30
deStruct: Accurate Rearrangement Detection using Breakpoint Specific RealignmentPreprint
McPherson, A., Shah, S. P., & Şahinalp, S. C. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/117523 · Cited by 18
Self-citationTargeting Programmed Cell Death 1 in Ovarian Cancer
Homicskó, K., & Coukos, G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7785 · Cited by 17
Funnell, T., Zhang, A., Shiah, Y.-J., Grewal, D. S., Lesurf, R., McKinney, S. E., Bashashati, A., Wang, Y. K., Boutros, P. C., & Shah, S. P. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/267500 · Cited by 8
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,296
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
Metadata
- Authors
- Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., LeDoux, S., Cochrane, D. R., Lim, J. L. P., Yang, W., Roth, A., Smith, M. A., Ho, J., Tse, K., Zeng, T., Shlafman, I., Mayo, M. R., Moore, R., Failmezger, H., Heindl, A., Wang, Y. K., Bashashati, A., Grewal, D. S., Brown, S. D., Lai, D., Wan, A. N. C., Nielsen, C. B., Huebner, C., Tessier-Cloutier, B., Anglesio, M. S., Bouchard-Côté, A., Yuan, Y., Wasserman, W. W., Gilks, C. B., Karnezis, A. N., Aparicio, S., McAlpine, J. N., Huntsman, D. G., Holt, R. A., Nelson, B. H., & Shah, S. P.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 173
- Issue
- 7
- Pages
- 1755-1769.e22
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2800654890
- Cited by
- 353
- References
- 54
- FWCI
- 39.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.